TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10405232
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy using lansoprazole (30 mg twice a day) plus clarithromycin (500 mg twice a day) and amoxicillin (1 g twice a day)
Study: 10405232
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy using omeprazole or lansoprazole plus clarithromycin and amoxicillin
Study: 7562290
Drug: Lactose-glucose polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-glucose polymer combination
Study: 7562290
Drug: Lactose-glucose polymer
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-glucose polymer combination and glucose polymers alone
Study: 1536959
Drug: rhGM‐CSF (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGM‐CSF (8 micrograms glycoprotein (5.5 micrograms protein)/kg/d, continuous IV infusion for 14 days)
Study: 6509876
Drug: Prompt phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prompt phenytoin sodium capsules (divided doses)
Study: 6509876
Drug: Prompt phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prompt phenytoin sodium capsules (single doses)
Study: 6509876
Drug: Phenytoin sodium
Normalized name: Phenytoin Sodium
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin sodium injection
Study: 19575366
Drug: 1.5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 microg/kg peginterferon alfa-2b weekly plus 800-1,400 mg ribavirin daily for 48 weeks (group A)
Study: 19575366
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored treatment duration (18-48 weeks; group B)
Study: 30352838
Drug: Tamoxifen 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 5 mg daily
Study: 12123540
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily
Study: 11759825
Drug: Tamoxifen (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (all doses)
Study: 11199932
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg starting dose for 12 weeks or 25 mg starting dose for 10 weeks)
Study: 9753259
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every morning
Study: 3065016
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of human zinc insulin (Monotard HM) with soluble human insulin (Actrapid HM)
Study: 3065016
Drug: Separate administration
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate administration of protamine insulin (Protaphan HM) with soluble human insulin (Actrapid HM)
Study: 26302441
Drug: Oral risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral risperidone
Study: 30148731
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-test kits and HIV testing information (study arm 3)
Study: 30148731
Drug: Oral HIV
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HIV self-test kits
Study: 16428249
Drug: Ranitidine bismuth
Normalized name: RANITIDINE BISMUTH CITRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine bismuth citrate 400 mg and clarithromycin 500 mg twice daily for two weeks
Study: 9678123
Drug: Low-dose monophasic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose monophasic combined oral contraceptive (100 micrograms levonorgestrel/20 micrograms ethinylestradiol)
Study: 31675102
Drug: All fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All fremanezumab groups (quarterly and monthly combined)
Study: 27385305
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no systemic therapy)
Study: 10434812
Drug: Midazolam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.3 mg kg‐1 followed by 0.15 mg kg‐1 h‐1)
Study: 10434812
Drug: Propofol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.5 mg kg‐1 followed by 10‐6 mg kg‐1 h‐1)
Study: 205633
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose ethanol treatment
Study: 205633
Drug: Chlordiazepoxide treatment
Normalized name: Chlordiazepoxide
DrugBank: Chlordiazepoxide (DB00475)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlordiazepoxide treatment
Study: 16412857
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin (ATV)
Study: 8378661
Drug: Simvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10 mg q.p.m. initially, increased to 40 mg q.p.m. for 64% of patients after 18 weeks)
Study: 8378661
Drug: Gemfibrozil (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil (900 mg q.p.m.)
Study: 3796783
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein intake (0.4 g/kg/day) supplemented with keto analogues of essential amino acids
Study: 3796783
Drug: Standard low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard low protein diet (0.6 g/kg/day)
Study: 26935962
Drug: Extraction group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction group (multiband treatment plus isolated extraction of mandibular teeth)
Study: 22644342
Drug: AST-120 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 2 g administered simultaneously with triazolam 0.25 mg
Study: 7750306
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP), 400 micrograms, two times daily
Study: 2248822
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with adrenaline 5 micrograms ml‐1
Study: 7028536
Drug: Acipimox 150
Normalized name: acipimox
DrugBank: Acipimox (DB09055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 150 mg
Study: 8444273
Drug: Acipimox 250
Normalized name: acipimox 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acipimox 250 mg
Study: 28108059
Drug: Cognitive‐Behavioral Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐Behavioral Group Therapy (CBGT)
Study: 21352660
Drug: Nebulized bronchodilator
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized bronchodilator + oxygen + forward‐leaning posture
Study: 17355549
Drug: Active preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active preparation (cannabis-based medicine containing THC and CBD)
Study: 15566533
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of patient records for SP visits
Study: 11572286
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B 40
Study: 10622084
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin 50 IU
Study: 10622084
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin 100 IU
Study: 9541513
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal calcitonin 200 IU
Study: 10331733
Drug: Rifapentine 300
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 300 mg daily
Study: 30670438
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg daily
Study: 10331733
Drug: Rifapentine 600
Normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifapentine 600 mg every 3 days
Study: 1674842
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac (SOI) before activated charcoal (AC)
Study: 7007060
Drug: Clonidine (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.4 +/- 0.15 mg/day)
Study: 31768697
Drug: PF-06439535 plus
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06439535 plus chemotherapy
Study: 31768697
Drug: bevacizumab-EU plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab-EU plus chemotherapy
Study: 30988146
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg, intravenously/orally, twice daily for 10 days
Study: 11961019
Drug: Modified peritoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified peritoneal dialysis prescription to achieve a peritoneal creatinine clearance (pCrCl) of 60 L/wk per 1.73 m(2)
Study: 27904912
Drug: Radial extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radial extracorporeal shock wave therapy (rESWT) - 3 sessions, each one week apart, 2,000 rESWT impulses per session, positive energy flux density 0.10-0.16 mJ/mm2
Study: 26008634
Drug: β‐alanine (3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: β‐alanine (3.2 g/day)
Study: 10770191
Drug: IGF‐I/IGFBP‐3 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGF‐I/IGFBP‐3 (2 mg/kg‐day) by continuous sc infusion for 2 weeks
Study: 9432523
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg morning dose)
Study: 9432523
Drug: Antiepileptic drugs
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drugs (AEDs) only
Study: 8260309
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion (CSCI) of morphine 30 micrograms kg‐1 h‐1 after a bolus of 0.1 mg kg‐1 i.v. at the end of the operation
Study: 30827716
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) on postoperative day 0 (POD 0)
Study: 30827716
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) on postoperative day 1 (POD 1)
Study: 21457353
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of AB chips and OM
Study: 2433195
Drug: No hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No hormone therapy (control group)
Study: 18562790
Drug: Antioxidant supplementation
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant supplementation (152 mg vitamin C/day and 50 mg vitamin E/day)
Study: 12469707
Drug: Various doses
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various doses of estrogen (0.3 mg CEE, 0.25 mg 17beta‐estradiol, transdermal patches delivering 20 microg 17beta‐estradiol, intranasal methods delivering 100-400 microg 17beta‐estradiol, 0.625 mg CEE, 0.5 mg 17beta‐estradiol) with or without progestogen.
Study: 12469707
Drug: Progestogen addition
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestogen addition to estrogen therapy in women with intact uterus.
Study: 8460344
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) vaccination of recombinant HB vaccine
Study: 8460344
Drug: IM booster
Normalized name: SAGE OIL 4.3 mg in 50 mL / EUCALYPTOL 13 mg in 50 mL TOPICAL OIL [Slim Booster with natural slimming activators]
Approvals — FDA: no, EMA: no, PMDA: no
Description: IM booster dose given 10 months after the third injection
Study: 3895410
Drug: Emepronium carrageenate
Normalized name: emepronium carrageenate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emepronium carrageenate (EC) 1000 mg
Study: 21783298
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of tramadol IM
Study: 20738456
Drug: 0.05% chlorhexidine/herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% chlorhexidine/herbal extract combination
Study: 1104246
Drug: 0.1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% chlorhexidine solution
Study: 16953808
Drug: Depression screening
Normalized name: Nerve depressants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depression screening and treatment
Study: 14971519
Drug: Intradermal vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal vaccination at a dose of 0.1 ml, 2 microg, administered at 5 positions, 4 vaccinations at months 0, 1, 2, and 6 (M0, M1, M2, M6)
Study: 14971519
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination at a dose of 1.0 ml, 20 microg, administered at 2 positions, 4 vaccinations at months 0, 1, 2, and 6 (M0, M1, M2, M6)
Study: 22337211
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (education, muscle stretching, exercises, homework for nine treatments in 6 weeks)
Study: 22184305
Drug: Cefazolin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin (2 g) administered before skin incision
Study: 17971285
Drug: Risedronate 5
Normalized name: risedronate 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 5 mg daily for 6 months
Study: 8912780
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (intervention)
Study: 17132970
Drug: Memantine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (20 mg per day)
Study: 11154169
Drug: Lansoprazole or
Normalized name: lansoprazole Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole or Omeprazole with antibiotics
Study: 9323749
Drug: Assertive community
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assertive community treatment
Study: 8403909
Drug: NORPLANT II
Approvals — FDA: no, EMA: no, PMDA: no
Description: NORPLANT II contraceptive implant
Study: 3520426
Drug: Monthly maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly maintenance therapy
Study: 19081527
Drug: Infliximab induction
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab induction (5 mg/kg/dose) at weeks 0, 2, and 6; maintenance therapy every 8 or 12 weeks
Study: 16093871
Drug: Pantoprazole 20
Normalized name: pantoprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole 20 mg on demand for 6 months
Study: 11870412
Drug: Cacit D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cacit D3 (1000 mg Ca and 880 IU vitamin D) taken as a single morning dose
Study: 11870412
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no drug intake)
Study: 7584524
Drug: Moxonidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.3 mg)
Study: 7011226
Drug: Aspirin (1,300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (1,300 mg daily) and dipyridamole (100 mg daily)
Study: 30736832
Drug: Aerobic-based exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerobic-based exercise intervention (thrice-weekly, moderate-intensity aerobic exercise supplemented with isometric resistance exercise)
Study: 30953791
Drug: Inspiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inspiratory muscle training (IMT) at 50% maximum inspiratory pressure (MIP) for 4 weeks, 30 breaths twice daily
Study: 30953791
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (15% MIP for 4 weeks, 30 breaths twice daily)
Study: 25307931
Drug: Ustekinumab (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (with dosing adjustments)
Study: 31769212
Drug: Ustekinumab (overall
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (overall treatment)
Study: 21898590
Drug: Denosumab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (60 mg subcutaneously every 6 months for 3 years)
Study: 12458383
Drug: Glucomannan +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucomannan + rifaximin (400 mg twice daily for 7 days every month)
Study: 11148445
Drug: Oral mesalazine
Normalized name: mesalamine Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral mesalazine 4 g
Study: 11148445
Drug: Combined mesalazine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined mesalazine 2 g orally plus 2 g rectally as a liquid enema
Study: 10648334
Drug: Acetaminophen 20
Normalized name: acetaminophen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 20 mg/kg (AS)
Study: 10648334
Drug: Acetaminophen 40
Normalized name: acetaminophen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 40 mg/kg (AL)
Study: 12850
Drug: Atenolol 300
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 300 mg/day
Study: 776350
Drug: Methyldopa 750
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 750 mg/day
Study: 12850
Drug: Methyldopa 1500
Normalized name: Methyldopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methyldopa 1500 mg/day
Study: 12850
Drug: Atenolol 150
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atenolol 150 mg/day and Methyldopa 750 mg/day (combined treatment)
Study: 12850
Drug: Methyldopa (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyldopa (lower dose)
Study: 28778047
Drug: Metformin in
Normalized name: Product containing metformin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin in rats
Study: 15948237
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/d for 6 months (group 1 and group 2)
Study: 15948237
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg/d for 12 months (group 1 and group 2)
Study: 15948237
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment, group 3 and group 4)
Study: 1569240
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketorolac
Study: 2676649
Drug: Doleron (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doleron (two tablets: 150 mg dextropropoxyphene napsylate, 350 mg aspirin, 150 mg phenazone)
Study: 26323054
Drug: manual-guided cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: manual-guided cognitive behavioral therapy (CBT) for insomnia
Study: 10065089
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with 5-FU + FA
Study: 25145487
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1,200 mg/day)
Study: 27761741
Drug: multisite treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: multisite treatment of bifrontal tDCS before bilateral auditory cortex tRNS
Study: 17828086
Drug: Sinuforte monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinuforte monotherapy in a single daily dose for 7 days
Study: 27711089
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of serenoa repens, selenium and lycopene extract + bromelain and methylsulfonylmethane extract with levofloxacin 500 mg o.d. for 14 days (Group A)
Study: 12431356
Drug: DTPw-HB vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB vaccine alone
Study: 12431356
Drug: DTPw-HB/Hib pentavalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HB/Hib pentavalent vaccine
Study: 12431356
Drug: DTPw/Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw/Hib vaccine
Study: 9867443
Drug: GIK (glucose,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIK (glucose, insulin, and potassium infusion)
Study: 7872278
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg t.i.d. azithromycin, tetracycline 500 mg q.i.d., bismuth subsalicylate 2 tablets q.i.d.
Study: 113370
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing 5‐chloro‐8‐hydroxyquinoline, gentamycin and fluprednyliden‐21‐acetate
Study: 29397376
Drug: semaglutide 0·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 0·5 mg
Study: 29397376
Drug: dulaglutide 1·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: dulaglutide 1·5 mg
Study: 29397376
Drug: dulaglutide 0·75
Approvals — FDA: no, EMA: no, PMDA: no
Description: dulaglutide 0·75 mg
Study: 29397376
Drug: semaglutide 1·0
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide 1·0 mg
Study: 22266175
Drug: 1mg oral
Normalized name: AXITINIB 1MG ORAL TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg oral 17‐β estradiol
Study: 12478899
Drug: L-OHP plus
Normalized name: L-OHP
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-OHP plus HCPT
Study: 1112230
Drug: High-titre rubella
Normalized name: rubella virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-titre rubella immunoglobulin administered intramuscularly (20 ml)
Study: 31792258
Drug: Pegylated liposomal
Normalized name: doxorubicin HCl pegylated liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegylated liposomal doxorubicin (PEG‐LG) 40 mg/m2 plus cyclophosphamide (CPM) 600 mg/m2 followed by docetaxel (DTX) 85 mg/m2, administered in four cycles on a 21-day schedule.
Study: 22542122
Drug: fesoterodine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: fesoterodine therapy (4-8 mg daily)
Study: 17993029
Drug: 18% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% carbamide peroxide whitening gel
Study: 15679130
Drug: fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 2 microg/kg and etomidate 0.3 mg/kg